Compare Alcon AG (ALC) vs BigBearai Holdings Inc (BBAI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs BigBearai Holdings Inc — how do they compare? Alcon AG trades at $66.95 (market cap $32.69B), while BigBearai Holdings Inc trades at $3.3 (market cap $1.64B). The key difference: Alcon AG is far larger — about 19.9× BigBearai Holdings Inc's market cap, and Alcon AG pays a 0.54% dividend while BigBearai Holdings Inc pays none. Which is the better fit depends on your goals.
| ALC | BBAI | |
|---|---|---|
Market Cap | $32.69B | $1.64B |
Sector | Health | Technology |
52-Week High | $92.22 | $8.91 |
52-Week Low | $62.02 | $3.05 |
Enterprise Value | $36.28B | $1.32B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
BBAI trades at $3.58, up 1.42% today, but technical indicators signal a bearish trend with strong selling pressure. The company reported a net loss of $293.91 million in 2025, with negative profit margins and cash flow from operations. Recent news highlights expansion into AI-powered airport security and government contracts, though high SG&A expenses and persistent losses remain concerns. Analyst consensus is cautious, with 75% hold ratings.
The outlook is challenged by ongoing losses and rich valuation, but growth in AI contracts and backlog offers potential upside. Key risks include execution on profitability, competitive pressures, and reliance on government spending. Investors should weigh the high-risk, high-reward profile amid volatile market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →
